Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings-Reference-Cited by-同舟云学术

Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings

Published:2022-06-06 Issue:1 Volume:25 Page:741-749
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Blauvelt Andrew¹^ORCID,Shi Nianwen²^ORCID,Murage Mwangi J.³^ORCID,Kern Scott A.³,Somani Najwa³,Burge Russel³⁴^ORCID,Ridenour Terri L.³,Lew Carolyn R.²,Zimmerman Nicole M.²^ORCID,Zhu Baojin³

Affiliation:

1. Research Excellence & Personalized Patient Care, Oregon Medical Research Center, Portland, OR, USA

2. Truven Health Analytics, Truven Health Analytics, IBM Watson Health, Cambridge, MA, USA

3. Eli Lilly and Company, Indianapolis, IN, USA

4. University of Cincinnati, Cincinnati, OH, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2081417

Reference31 articles.

1. The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study

2. The Burden of Skin and Subcutaneous Diseases in the United States From 1990 to 2017

3. Psoriasis prevalence among adults in the United States

4. Evaluating the economic burden of psoriasis in the United States

5. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aloe vera-loaded natural rubber latex dressing as a potential complementary treatment for psoriasis;International Journal of Biological Macromolecules;2023-07